Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Gains from Sales and Divestitures: 2019-2025

Historic Gains from Sales and Divestitures for BridgeBio Pharma (BBIO) over the last 6 years, with Jun 2025 value amounting to $1.9 million.

  • BridgeBio Pharma's Gains from Sales and Divestitures fell 0.88% to $1.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $1.9 million, marking a year-over-year decrease of 0.88%. This contributed to the annual value of $3.8 million for FY2024, which is 5.58% up from last year.
  • According to the latest figures from Q2 2025, BridgeBio Pharma's Gains from Sales and Divestitures is $1.9 million, which was up 120.75% from $879,051 recorded in Q1 2025.
  • BridgeBio Pharma's Gains from Sales and Divestitures' 5-year high stood at $3.8 million during Q4 2024, with a 5-year trough of $336,790 in Q1 2022.
  • In the last 3 years, BridgeBio Pharma's Gains from Sales and Divestitures had a median value of $1.9 million in 2024 and averaged $2.1 million.
  • Per our database at Business Quant, BridgeBio Pharma's Gains from Sales and Divestitures crashed by 47.59% in 2022 and then surged by 117.14% in 2023.
  • Quarterly analysis of 5 years shows BridgeBio Pharma's Gains from Sales and Divestitures stood at $1.6 million in 2021, then grew by 24.52% to $2.0 million in 2022, then soared by 84.67% to $3.6 million in 2023, then rose by 5.58% to $3.8 million in 2024, then dropped by 0.88% to $1.9 million in 2025.
  • Its Gains from Sales and Divestitures was $1.9 million in Q2 2025, compared to $879,051 in Q1 2025 and $3.8 million in Q4 2024.